Biotech Values

[ThomasS]

MNTA: I should point out that the profit-sharing arrangement for M356 Copaxone is favorable for MNTA in a manner which probably won't be repeated for the other 2 compounds M178/249.
M356 was a MNTA compound before the Sandoz collaboration; hence, the future terms may well be quite less, although substantial, depending on the drug.